Vanguard Group
NWBO

Vanguard Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Vanguard Group’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,378,939
Closed -$752K – 4152
2016
Q3 		$752K Sell
1,378,939
-227,956
-14% -$104K ﹤0.01% 3651
2016
Q2 		$934K Sell
1,606,895
-446,494
-22% -$477K ﹤0.01% 3624
2016
Q1 		$3M Buy
2,053,389
+235,776
+13% +$465K ﹤0.01% 3209
2015
Q4 		$5.82M Buy
1,817,613
+151,206
+9% +$727K ﹤0.01% 2920
2015
Q3 		$10.4M Buy
1,666,407
+66,603
+4% +$623K ﹤0.01% 2589
2015
Q2 		$15.9M Buy
1,599,804
+326,197
+26% +$2.86M ﹤0.01% 2453
2015
Q1 		$9.39M Buy
1,273,607
+54,287
+4% +$365K ﹤0.01% 2679
2014
Q4 		$6.52M Buy
1,219,320
+96,886
+9% +$496K ﹤0.01% 2752
2014
Q3 		$5.64M Buy
1,122,434
+146,575
+15% +$901K ﹤0.01% 2761
2014
Q2 		$6.55M Buy
975,859
+128,231
+15% +$816K ﹤0.01% 2712
2014
Q1 		$6.14M Buy
847,628
+134,370
+19% +$796K ﹤0.01% 2728
2013
Q4 		$2.69M Buy
713,258
+340,567
+91% +$1.32M ﹤0.01% 3073
2013
Q3 		$1.25M Buy
372,691
+2,120
+0.6% +$7.38K ﹤0.01% 3306
2013
Q2 		$1.24M Buy
+370,571
New +$1.34M ﹤0.01% 3241

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

Vanguard Group's NWBO Position: Q4 2016 in Review

Vanguard Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 1,378,939 shares — an estimated $752K sold.

Vanguard Group first reported a position in NWBO in Q2 2013 and held it in 14 quarters. The position peaked at $15.9M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Vanguard Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Vanguard Group sold 1,378,939 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $752K.
  • Vanguard Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and held it in 14 quarters.
  • Vanguard Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $15.9M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Vanguard Group's 13F filing for Q4 2016, filed 14 Feb 2017.